Comparing the Impact of Tetrahydrocannabinol on 30-Day Readmission Rates and Hospital Length of Stay in Patients With Depression.

Mohammed E. Khedr, Yunjin Lee, Muhammed A. Mirza, Humberto Jimenez, Daniel Greer

BACKGROUND AND OBJECTIVES: Delta-9-tetrahydrocannabinol (THC), the psychoactive constituent of cannabis, continues to be critically evaluated for its potential therapeutic efficacy and associated safety concerns in major depressive disorder (MDD). Length of stay and readmission rates are key indicators of treatment response and prognosis. With rising cannabis use, understanding the effects of THC is essential. The…